Accession NumberDB05032
TypeSmall Molecule

rEV131 is in development for allergic rhinitis, asthma and several inflammatory eye diseases. It is a topically delivered small protein that acts as an anti-inflammatory agent.

SynonymsNot Available
External IDs Not Available
Product Ingredients Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
UNIINot Available
CAS numberNot Available
WeightNot Available
Chemical FormulaNot Available
InChI KeyNot Available
InChINot Available
IUPAC NameNot Available
SMILESNot Available

Investigated for use/treatment in allergic reaction, allergic rhinitis, and cataracts.

Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action

rEV131 is smaller than therapeutic antibodies and its compact structure gives good bioavailablity by a number of routes including: injected, inhaled, intraperitoneal, topical (ocular and nasal). The molecule is thermo-stable and can be stored in solution for more than 18 months at room temperature without significant loss of activity. This is an attractive feature for a protein drug candidate.

rEV131 is a novel histamine binding protein that modulates the immediate inflammatory response largely caused by the release of pre-formed histamine from mast cells in the skin. This molecule binds histamine at two active sites, one of which has an affinity for histamine 10 - 100 times higher than any known histamine receptor. This enables rEV131 to out compete the body's natural receptors and prevent histamine from reaching and activating them.

There are at least four different natural histamine receptors. The most recently discovered H4 receptor, was described in 2001, and appears to be involved in the late phase inflammatory process. rEV131 is understood to be the only drug candidate in clinical development, which prevents activation of the H4 receptor.

rEV131 has demonstrated activity against both early and late phase inflammation in clinical and preclinical studies. This differentiates it from approved treatments: anti-histamines used in early phase inflammation and corticosteroid therapies, which are used predominantly in late phase inflammation. A favourable safety profile and a variety of delivery routes provide additional potential advantages for rEV131 over existing therapies.

TargetKindPharmacological actionActionsOrganismUniProt ID
Histamine H4 receptorProteinunknownNot AvailableHumanQ9H3N8 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half life

Approximately 8 hours

ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Drug Interactions Not Available
Food InteractionsNot Available
Synthesis ReferenceNot Available
General ReferencesNot Available
External LinksNot Available
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
1, 2Unknown StatusPreventionPollen Allergy1
2Unknown StatusNot AvailableOcular inflammatory conditions1
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Experimental PropertiesNot Available
Predicted PropertiesNot Available
Predicted ADMET featuresNot Available
Mass Spec (NIST)Not Available
Spectrum TypeDescriptionSplash Key
ClassificationNot classified


Pharmacological action
General Function:
Histamine receptor activity
Specific Function:
The H4 subclass of histamine receptors could mediate the histamine signals in peripheral tissues. Displays a significant level of constitutive activity (spontaneous activity in the absence of agonist).
Gene Name:
Uniprot ID:
Uniprot Name:
Histamine H4 receptor
Molecular Weight:
44495.375 Da
Drug created on October 21, 2007 16:23 / Updated on August 17, 2016 12:24